



December 14, 2010

Michele Horwitz
AACC Membership Director

Dear Michele:

It is with great respect and enthusiasm that I support the nomination of Russ Warnick for the Outstanding Contributions in a Selected Area of Research award. I have been a member of the AACC and the Lipoproteins and Vascular Diseases Division (LVDD) for 19 years, and during my tenure with the AACC I have been inspired by Russ' contribution to service and research in clinical chemistry.

Russ is perhaps best known for the development of an important precipitation assay for HDL cholesterol, but he also co-founded the Lipid and Lipoprotein Division and has served as editor of our newsletter for many years. He remains the foremost expert on lipid and lipoprotein measurement and lipoprotein subclasses, and he has been a strong advocate and leader in cholesterol and lipoprotein standardization initiatives. He has also been a mentor to many of us who have served with the LVDD.

It would be tiresome to list all of his accomplishments in support of his nomination, which you can read for yourself from his resume, but many of his accomplishments are worth mentioning: Over 100 peer-review publications and book chapters relating to lipids and lipoproteins; co-editor of perhaps the most important textbook on lipid and lipoprotein testing (Handbook of Lipoprotein Testing); and winner of the major LVDD awards (Gerald Cooper Award, Bennie Zak Award, and Recognition Award for outstanding leadership, performance, and dedicated service as Chair). Russ has also organized and participated in working groups devoted to standardization of lipid and lipoprotein measurements.

Russ has been the most influential lipid clinical chemist of the past twenty years, and this award is well-deserved. There is no one more deserving of this award than G. Russell Warnick.

Best regards,

A handwritten signature in black ink that reads "John Contois". The signature is fluid and cursive, with the first name "John" and last name "Contois" clearly legible.

John H. Contois, PhD, DABCC, FACB
Manager, Research and Development
Maine Standards Company

G. Russell Warnick M.S., M.B.A.

Pacific Biometrics Research Foundation

24415 SE 156th Street

Issaquah, WA 98027

(425) 392-5725

grwarnick@hotmail.com

WORK EXPERIENCE

Chief Scientific Officer and Sr. Vice President for Laboratory Operations, Berkeley HeartLab, Inc. (2007)

Vice President for Laboratory Operations, Berkeley HeartLab, Inc. (2005-present)

President, Warnick&Co (1998-present)

President, Pacific BioMetrics Research Foundation (1990-present)

Founder and Chief Scientific Officer, Pacific BioMetrics, Inc. (1996-1998)

President, Pacific BioMetrics, Inc., (1990-1996)

Director, Lipoprotein Laboratory, Northwest Lipid Research Center (1986-1990)

Laboratory Manager, Northwest Lipid Research Center (1982-1986)

Assistant Laboratory Director, Northwest Lipid Research Center (1976-1982)

Research Scientist, University of Washington (1982-1990)

Research Associate, University of Washington, Department of Medicine (1973-1990)

EDUCATION

M.B.A., City University, Seattle (1982)

M.S. Biochemistry, Utah State University (1970)

B.A. Chemistry, Utah State University (1968)

ACADEMIC AND PROFESSIONAL HONORS

Section Award for outstanding contributions to Clinical Chemistry through Science or Technology, American Association for Clinical Chemistry, Inc. Northern California Section (2009)

Gerald Cooper Award, American Association for Clinical Chemistry, Inc. Lipoproteins and Vascular Diseases Division (2006)

Bennie Zak Award for Research, American Association for Clinical Chemistry, Inc. Lipoproteins and Vascular Diseases Division (1993)

AACC Lipids and Lipoprotein Div Recognition Award for outstanding leadership, performance, and dedicated services as chair (1985 – 89)

Distinguished Honor Graduate, Medical Service Corps Officer's Basic Course (1971)

Research Assistantship, Utah State University (1968)

Distinguished Military Graduate, R.O.T.C. (1968)

Graduate Cum Laude in Chemistry (1968)
Phi Eta Sigma Scholastic Honorary Fraternity (1967)
NSF Undergraduate Fellowship (1966)
Academic Scholarship, Utah State University (1962)

CERTIFICATION

Bioanalytical Laboratory Manager, American Board of Bioanalysts (1983)

PROFESSIONAL ORGANIZATIONS

National Lipid Association (2007)
American Society for Bone and Mineral Research (1997)
Association of Clinical Pharmacology (1993)
Organization of Regulatory and Clinical Associates (ORCA, 1993)
National Committee for Clinical Laboratory Standards (NCCLS, 1993)
Hands to Clinical Labs of Third World Countries (1988)
International Platform Association (1988)
American Association for the Advancement of Science (1986)
American Oil Chemists' Society (1984)
Nutrition Division, Lipoproteins and Vascular Diseases Division, Laboratory Information Systems Division: American Association for Clinical Chemistry (1984)
Clinical Laboratory Management Association (1982)
The Society of Armed Forces Medical Laboratory Scientists (1980)
American Heart Association, Arteriosclerosis Council (1979)
Washington State Heart Association (1979)
American Association for Clinical Chemistry (1974)
American Chemical Society (1963)

OFFICES HELD

Chair, Pacific Northwest Section, American Association for Clinical Chemistry (2001)
Chair-elect, Pacific Northwest Section, American association for Clinical Chemistry (2000)
Past Chairman, Lipids and Lipoproteins Division, American Association for Clinical Chemistry (1990)
Chairman, Lipids and Lipoproteins Division, American Association for Clinical Chemistry (1986-1989)
Chairman, Laboratory Methods Committee, Lipid Research Clinics Program (1981)
Secretary, Phi Eta Sigma Scholastic Honorary Fraternity (1968)

NATIONAL RESPONSIBILITIES

Associate Editor, Journal of Clinical Lipidology (2007 – present)
Advisor, Healthcare Technology Foundation, Tokyo, Japan (2006)

Co-Chairman, Joint Japan-US Meeting for Standardization of Direct LDL Methods sponsored by Japan Medical Technology Foundation and Pacific Biometrics Research Foundation (2004, 2005, 2006 & 2007)

Member, Working Group, AHA/CDC Scientific Statement: Markers of Inflammation and Cardiovascular Disease (2003)

Member, Nominating Committee, Lipoproteins and Vascular Diseases Division, American Association for Clinical Chemistry (2000-2001)

Member, Program Committee, Frontiers in Lipoproteins and Vascular Disease Research Meeting, Lipoproteins and Vascular Diseases Division, American association for Clinical Chemistry (2000)

Member, Panel to develop Standardized Laboratory Reporting Format for Cholesterol, Triglycerides, LDL and HDL (1999)

Member, Bone Marker Task Force, Centers for Disease Control and Prevention (1998-2000)

Member, Education Committee, Clinical and Diagnostic Immunology Division, American Association for Clinical Chemistry (1998-present)

Member, Government Relations Committee, American Association for Clinical Chemistry (1994-1999)

Advisor, Subcommittee for Cholesterol Reference Materials, National Committee for Clinical Laboratory Standards (1992)

Member, Contributed Papers Committee, American Association for Clinical Chemistry National Meeting (1992)

Editor, *The Fats of Life*, Newsletter of the Lipoproteins and Vascular Diseases Division, American Association for Clinical Chemistry, (1990-present)

Organizing Chairman, Workshop for Manufacturers, Standardization of Lipid and Lipoprotein Methods, International Federation of Clinical Chemistry Meeting, San Francisco, CA, July 1990

Chairman, Nominating Committee, American Association for Clinical Chemistry Lipoproteins and Vascular Diseases Division (1989 and 1990)

Lieutenant Colonel, Medical Service Corps, U.S. Army (1990)

Member, Working Group on Lipoprotein Measurement, National Cholesterol Education Program, (1989)

Advisor, Editorial Board of the Journal of Exercise and Nutrition Intervention (1988)

Member, Committee for Contributed Papers, American Association for Clinical Chemistry National Meeting (1988)

Advisor, Subcommittee on Apolipoproteins, National Committee for Clinical Laboratory Standards (1987)

Member, Ad hoc Review Committees on HDL and LDL Cholesterol Measurement, American Association for Clinical Chemistry (1987)

Member, Executive Committee, Laboratory Standardization Panel for Cholesterol, National Cholesterol Education Program (1987)

Member, Laboratory Standardization Panel for Cholesterol, National Cholesterol Education Program (1986)

Member, Standards Committee, American Association for Clinical Chemistry (1985)

Adjunct Scientist, NIH Study of Cardiovascular Disease, People's Republic of China (1983-1992)

Major, Medical Service Corps, U.S. Army Individual Mobilization Augmentee, Madigan Army Medical Center (1981)

Member, Quality Control Subcommittee, Lipid Research Clinics Program (1979)

Member, Laboratory Methods Committee, Lipid Research Clinics Program (1973)

LOCAL RESPONSIBILITIES

Volunteer Tutor, Coaching to College Program, The Treehouse for Kids (2001)

Member, Board of Directors, The Bridge Foundation (1999-2001)

Member, Organizing Committee for 1989 Northwest Regional Meeting, American Association for Clinical Chemistry (1988)

Member, Advisory Committee Core Laboratory, Diabetes Endocrinology Research Center (1987)

PROFESSIONAL CONSULTING

PPD, Scientific Advisory Board (2007)

DiaDexus, Diagnostic product development (2002-present)

Nichols Diagnostics Inc., Directed clinical trial to determine Vitamin D distributions (2004)

OmegaMetrix, Development of Specialty Laboratory for characterization of fatty acids (2003-present)

Associated Regional and University Pathologists, Lipoprotein subclass analysis methods (2003-present)

Japan Immunoresearch Laboratories Co., LTD., Diagnostic product development (2000-present)

Quantimetrix Corp., Consultant for marketing strategy (2000-present)

Metrika Laboratories, Diagnostics development, (1994- present)

Polymedco Inc., Market development for diagnostic products (2001-present)

Covance Central laboratory, Technical consultant for lipid testing services (2000-2001)

Children's Hospital, Boston MA, Business development consultant (1999-2000)

Otsuka American Pharmaceutical Corporation, Consultant on market development for RLP-C diagnostic (1995-2000)

Genzyme Corporation, Development and evaluation of commercial reagent systems and testing methods for measuring lipoproteins, (1989-2000)

Cholestech Corp., Scientific Advisory Committee, Diagnostics development, (1988-1999)

Core Laboratory for Clinical Studies, Washington University, Strategic business development (1998)

Merck, Consultant to Lovastatin AFCAPS study, (1994)

ChemTrak, Diagnostics development, (1989-1994)

Micronix Inc., Consultation, laboratory support and clinical evaluations for Phase II development program of threshold cholesterol analysis device, (1991)

Battelle Nikkei, Clinical and research advisement in biochemical research and analysis, Nikkei Arteriosclerosis Research Center, (1990)

Bristol Myers Squibb, Reviewing qualifications and capabilities of central study laboratories, (1989)

Occasional consultant to the following corporations: ActiMed; Baxter, Inc.; Beckman Instruments, Inc.; Boehringer Mannheim Diagnostics Inc.; Eastman Kodak Company; Helena Laboratories; J & D Scientific, Inc.; Medical Analysis Systems, Inc.; Miles Inc.; Oregon Research Institute; SmithKline Beecham Laboratories

NATIONAL AND INTERNATIONAL LECTURES

1. American Society of Clinical Pathologists, Chicago, IL, April, 1978. Measurement of High Density Lipoproteins.
2. NHLBI HDL Methodology Workshop, San Francisco, CA. March 12-14, 1979. Precipitation of Apolipoprotein B Containing Lipoproteins by Different Methods.
3. University of Utah Seminar, Salt Lake City, UT, April 1979. Lipoprotein measurement.
4. Workshop for Clinical Chemistry, Salt Lake City, UT, Aug. 29-31, 1979. High Density Lipoproteins: Characteristics, Significance, Measurement.
5. Hyland Diagnostics, Round Lake, IL, January 28, 1980. HDL Measurement.
6. National Institutes of Health, Bethesda, MD, March 19, 1981. Methodology of HDL Cholesterol Determination.
7. American Association for Clinical Chemistry National Meeting, Lipoprotein Workshop, Kansas City, KS, July 19, 1981. Lipid and Lipoprotein Methods.
8. American Association for Clinical Chemistry National Meeting, Lipoprotein Workshop, Anaheim, CA, August 9, 1982. Lipid and Lipoprotein Methods.
9. Tripler Army Medical Center, Honolulu, HI, March 1984. Lipoprotein Measurement.
10. National Heart, Lung, and Blood Institute Workshop on the Lipid Research Clinics Coronary Primary Prevention Trial, Bethesda, MD, June 6-7, 1984. Lipid Quantification: From Acids to Enzymes.
11. American Association for Clinical Chemistry National Meeting, Lipoprotein Workshop, Washington, D.C., July 29, 1984. Lipoprotein Quantification Methods.
12. National Cholesterol Education Program Laboratory Standardization Panel, Bethesda, MD, April 9, 1986. Enzymic Methods for Cholesterol Measurement.
13. Cleveland Clinic, Cleveland, OH, May 1986. Lipoprotein Measurement.
14. American Association for Clinical Chemistry National Meeting, Washington, D.C., July 13-18, 1986. Current Lipid, Lipoprotein, and Apolipoprotein Methods for Assessing Risk for CHD.
15. International Symposium on Cholesterol Control and Cardiovascular Diseases: Prevention Therapy, Milan, Italy, July 7-9, 1987. Evaluation of Portable Analyzers for Cholesterol Determination.
16. American Association for Clinical Chemistry National Meeting, San Francisco, CA, July 19, 1987. Materials, Calibration and Control.
17. American Society of Clinical Pathologists Fall National Meeting, New Orleans, LA, October 24-30, 1987. Lipids: Practical Analytical Considerations.
18. National Bureau of Standards, Washington, D.C., January 7, 1988. Update on Lipid Standardization.
19. American Society of Clinical Pathologists Spring Meeting, Kansas City, April 16-21, 1988. Measurement of Cholesterol, Triglyceride and HDL Using Compact Analysis Systems.
20. American Association for Clinical Chemistry Annual Meeting, New Orleans, LA, July 25, 1988. Methods for Triglyceride, Total and HDL Cholesterol Determination.
21. National Heart, Lung and Blood Institute Cholesterol Screening Workshop, Washington, D.C., October 17, 1988. Overview and Performance Characteristics of Compact Analyzers.
22. American Society of Clinical Pathologists Fall Meeting, Las Vegas, NV, October 22-28, 1988. Cholesterol and Lipoproteins: A New Look at Lipids.

23. American Association for Clinical Chemistry Lipoproteins and Vascular Diseases Division, Washington D.C., October 21, Miami, FL, October 29, San Francisco, CA, November 18, 1988. National Cholesterol Education Program: Implications for the Laboratorian.
24. American Association for Clinical Chemistry Northeastern Sections Regional Conference, Springfield, MA, November 7-9, 1988. Symposium Chairperson: Current Guidelines for Detection and Treatment of Hypercholesterolemia.
25. Society of Armed Forces Laboratory Scientists National Meeting, San Antonio, TX, March 5, 1989. National Cholesterol Education Program: Implications for Laboratorians.
26. Medical Technology Association of Alaska Annual Meeting, Anchorage, AK, March 30-April 1, 1989. Measurement of Lipoproteins.
27. Pennsylvania Society for Medical Technology Annual Meeting, King of Prussia, PA, April 17-20, 1989. National Cholesterol Education Program: Recommendations for Measurement and Interpretation.
28. American Association for Clinical Chemistry National Meeting Manufacturers Workshop, Atlanta, GA, July 23, 1989. Issues Concerning Lipid Standardization.
29. American Association for Clinical Chemistry National Meeting, Atlanta, GA, July 25, 1989. Lipoprotein Workshop: Cholesterol Determination.
30. American Association for Clinical Chemistry Selected Topics, Atlanta, GA, July 23-27, 1989. Apolipoprotein E Isoform Analysis in Characterizing Atherogenic Risk.
31. American Association for Clinical Chemistry New York Section Fall Meeting, Rochester, NY, October 26-27, 1989. Beyond Total Cholesterol: Standardization of Measurements for LDL, HDL and Triglycerides.
32. American Society of Clinical Pathologists Fall Meeting, Washington, D.C., Oct. 28-Nov. 3, 1989. Cholesterol and Lipoproteins: A New Look at Lipids.
33. International Federation of Clinical Chemistry Bergmeyer Conference, Murnau, West Germany, November 4-7, 1989. Laboratory Measurements in Lipid Disorders: "How do we Measure?"
34. Second Annual Massachusetts Conference on Cholesterol, Cholesterol Education Program, American Heart Association, Framingham, MA, February 14, 1990. Laboratory Aspects of Lipid and Lipoprotein Measurements.
35. Medical College of Pennsylvania, Philadelphia PA, February 19, 1990. Lipid and Lipoprotein Analyses for Cardiovascular Risk Evaluation.
36. American Society of Clinical Pathologists Spring Meeting, San Francisco, CA, March 24-29, 1990. Cholesterol and Lipoproteins: A New Look at Lipids.
37. Reflotron HDL Cholesterol Workshop, Vienna, Austria, May 22, 1990. HDL Cholesterol Standardization.
38. Lipoprotein Measurement Workshop, Cape town, South Africa, July 2-5, 1990. Lecture: Laboratory Measurement of the Lipid and Lipoprotein Risk Factors for Coronary Heart Disease; Workshop: Lipid, Lipoproteins, and Apolipoprotein Assay.
39. University of Natal Mini Symposium: Lipoproteins and Cardiovascular Disease, Durban, South Africa, July 9, 1990. Lipids and Lipoproteins: A New Look at Lipids.
40. Mini Symposium: Lipoproteins and Cardiovascular Disease, Johannesburg, South Africa, July 12, 1990. Lipids and Lipoproteins: A New Look at Lipids.
41. American Association for Clinical Chemistry and Council of the NRSC (NCCLS) Manufacturers Workshop, San Francisco, CA, July 22, 1990. Standardization of Lipid and Lipoprotein Methods.
42. American Association for Clinical Chemistry XIV International Congress of Clinical Chemistry, San Francisco, CA, July 23, 1990. Workshop: Standardization and Clinical Utility of Lipid Determinations.
43. Northwest Medical Laboratory Symposium, October 24, 1990. Measurement and Interpretation of Cholesterol and Other Lipoprotein Risk.

44. Lorenzini Foundation, National Heart, Lung, and Blood Institute, NIH, and Baylor College of Medicine, International Symposium on Multiple Risk Factors in Cardiovascular Disease, Washington, D.C., December 10-12, 1990. HDL Cholesterol Measurement: Methodological Considerations and Laboratory Performance.
45. American Society of Clinical Pathologists Spring National Meeting, Nashville, TN, February 3, 1991. Cholesterol and Lipoproteins: A New Look at Lipids.
46. National Conference on Cholesterol and High Blood Pressure Control Boston University School of Medicine, Boston, MA, April 8, 1991. Standardization of HDL Cholesterol Measurements.
47. American Association for Clinical Chemistry, Washington, D.C., July 28-31, 1991. Manufacturers Workshop on Issues in Lipid and Lipoprotein Standardization.
48. American Association for Clinical Chemistry, Washington D.C., July 28-31, 1991. Roundtable: Standardization of HDL Cholesterol Measurement.
49. American Association for Clinical Chemistry, Washington, D.C., July 29, 1991. Workshop: Standardization and Clinical Utility of Lipid Determinations.
50. American Society of Clinical Pathologists Fall National Meeting, New Orleans, September 24, 1991. Cholesterol and Lipoproteins: A New Look at Lipids.
51. Eastman Kodak, Rochester, NY, November 22, 1991. Snapshots: Coronaries, Cholesterol and Kodak.
52. American Society of Clinical Pathologists Spring National Meeting, Boston, MA, April 3-4, 1992. Workshop: Cholesterol and Lipoprotein: A New Look at Lipids.
53. Associates of Clinical Pharmacology Annual Meeting, Miami Beach, FL, May 6, 1992. Workshop: Analytical Considerations in Lipid Analysis.
54. American Association for Clinical Chemistry Northern California Section, San Jose, CA, June 18, 1992. Lecture: Update on Measurement of Cholesterol and Lipoproteins.
55. American Association for Clinical Chemistry National Meeting, Chicago, IL, July 19, 1992. Manufacturers Workshop: Standardization of Lipid, Lipoprotein, and Apolipoprotein Testing.
56. American Association for Clinical Chemistry National Meeting, Chicago, IL, July 20, 1992. Roundtable: Standardization of HDL Cholesterol Measurement.
57. American Association for Clinical Chemistry National Meeting, Chicago, IL, July 21, 1992. Selected Topics: Innovative Electrophoretic Techniques for Lipoprotein Analysis.
58. American Association for Clinical Chemistry National Meeting, Chicago, IL, July 22, 1992. Workshop: New Developments in Measurement Systems for Lipids, Lipoproteins, and Apolipoproteins. Systems for Decentralized Testing.
59. Pacific Northwest Section, American Association for Clinical Chemistry, September 23, 1992. Seattle, WA, Update on Lipid and Lipoprotein Analysis.
60. American Society of Clinical Pathologists Fall National Meeting, Boston, MA, October 14, 1992. Cholesterol and Lipoproteins: A New Look at Lipids
61. American Society of Clinical Pathologists Teleconference, May 11, 1993. It's Time to Make HDL Measurements Accurate.
62. American Association for Clinical Chemistry National Meeting, New York, NY, July 12, 1993. Roundtable: Standardization of HDL Cholesterol Measurement.
63. American Association for Clinical Chemistry National Meeting, New York, NY, July 9-15, 1993. Workshop: Genzyme; A Routine, Direct LDL Cholesterol Assay.
64. American Association for Clinical Chemistry National Meeting, New York, NY, July 12, 1993. Symposia: Pre-Symptomatic Screening; Screening Strategies for Coronary Artery Disease Prevention.
65. University of Wisconsin, Madison, WI, August 4, 1993. "Back to the Future" of Lipids.

66. American Association for Clinical Chemistry Lipoproteins and Vascular Diseases Division Workshop, New Orleans, LA, July 17, 1994. Concepts in Lipid Measurements-Today's Challenges Highlighting Point-of-Care Testing. Evolving Technology in Lipid Testing.
67. American Association for Clinical Chemistry National Meeting, New Orleans, LA, July 18-21, 1994. Roundtable presentation: July 21, 1994, Standardization of HDL cholesterol measurement.
68. American Society of Clinical Pathologists, Spring Meeting, Washington, DC, April 9-14, 1994. Cholesterol and Lipoproteins: A New Look at Lipids.
69. Pacific Northwest Section, American Association for Clinical Chemistry Symposium and Instrumentation Exhibit, Seattle, WA, April 28-29, 1994. Regulatory issues impacting point of care testing.
70. American Association of Clinical Pathologists, Inc., Washington, DC, October 23-27, 1994. Cholesterol and Lipoproteins: A New Look at Lipids.
71. Genzyme Diagnostics, Clifton, NJ, December 6, 1994. LDL Cholesterol.
72. American Association for Clinical Chemistry National Meeting, Anaheim, CA, July 20, 1995. Roundtable: Standardization Of HDL Cholesterol Measurement.
73. American Society of Clinical Pathologists Fall National Meeting, New Orleans, LA, September 19, 1995. New Developments in Osteoporosis. Why All The Fuss?
74. American Society for Clinical Laboratory Science, Portland, OR, October 19, 1995. Measurement of HDL Cholesterol and LDL Cholesterol.
75. Pacific Northwest Conference for Primary Care Practitioners, Seattle, WA, November 3, 1995. Laboratory Measurement of LDL & HDL Cholesterol.
76. American Association for Clinical Chemistry National Meeting, Chicago, IL, August 1, 1996. Roundtable: Standardization of HDL Cholesterol Measurement.
77. American Association for Clinical Chemistry National Meeting, Atlanta, GA, July 21, 1997. Roundtable: Standardization of HDL Cholesterol Measurement.
78. American Association for Clinical Chemistry National Meeting, Chicago, IL, July 1998. Roundtable: Standardization of HDL Cholesterol Measurement.
79. American Association for Clinical Chemistry National Meeting, New Orleans, LA, July 29, 1999. Roundtable: Standardization of HDL Cholesterol Measurement.
80. American Association for Clinical Chemistry Audio Conference, October 1999. Speaker: Clinical Trials: Revenue Opportunities for your Laboratory.
81. Bone Turnover Markers: Biochemical and Clinical Perspectives, Geneva, Switzerland, March 24-25, 2000. Variation in Biochemical Markers of Bone Turnover: Sources, Quantification, Minimization.
82. VIII Jornados Centrifugas Laboratorio Metropolitano, Caracas, Venezuela, November 2000. International Lecturer: Utilization of Bone Markers in the Characterization of Osteoporosis.
83. VII Jornados Centrifugas Laboratorio Metropolitano, Caracas, Venezuela, November 2000. International Lecturer: Concepts of Laboratory Quality Control and Standardization.
84. American Association for Clinical Chemistry National Meeting, San Francisco, CA, July 24, 2000. Roundtable: Standardization of HDL Cholesterol Measurement.
85. American Association for Clinical Chemistry National Meeting, Chicago, IL, July 30, 2001. Roundtable: Standardization of Direct Methods for LDL and HDL Cholesterol Measurement.

86. American Association for Clinical Chemistry National Meeting, Orlando, FL, July 29, 2002. Roundtable: Standardization of Methods for LDL and HDL Cholesterol.
87. American Association for Clinical Chemistry National Meeting, Philadelphia, PA, July 21, 2003. Roundtable: Standardization of Methods for LDL and HDL Cholesterol.
88. Brazil Congress of Clinical Pathology, Rio de Janeiro, September 24, 2003, Lectures: hs-CRP and HDL Cholesterol: Analytical Aspects and Quality Assurance.
89. Southeast Section, American Association for Clinical Chemistry, February 24, 2004, LDL Subfraction Analysis for Predicting the Risk of Cardiovascular Disease.
90. American Association for Clinical Chemistry National Meeting, Los Angeles, CA, July 28, 2004. Roundtable: Standardization of Methods for LDL and HDL Cholesterol.
91. Brazil Congress of Clinical Pathology, Florianopolis, September 23, 2004, Lectures: The Emerging Role of Lipoprotein Subclasses in Evaluation of Hyperlipidemias and Metabolic Syndrome.
92. American Association for Clinical Chemistry National Meeting Orlando FL July 26th 2005. Roundtable: US-Japan Joint meeting for Standardization.
93. Brazil Congress of Clinical Pathology, Rio de Janeiro, October 22, 2005 Lipid Analysis Worldwide: A Business Perspective.
94. Japanese Association of Laboratory Medicine, Fukuoka Japan November 17, 2005. Lipid Analysis: Historic Overview.
95. National Institute of Health, Washington DC, May 24th 2006. Lipoproteins: Past, Present and Future.
96. AACC Capital Section, Washington DC, May 24th 2006. Lipoproteins: Past, Present and Future.
97. AACC Annual Meeting, San Diego, CA, July 17th 2007. HDL Subfraction Analysis and Diagnostic Utility.
98. AACC Annual Meeting (Denka Seiken Industry Workshop), San Diego, CA July 18th 2007. LDL Subclass measurement in CHD Risk Assessment and Measurement.
99. Scientific Advisory Board, Oslo, Norway, November 6, 2008. Cardiovascular Disease Management and Lipoprotein Analysis.
100. Merck & Co, Inc., Global Headquarters, Rahway, NJ, December 15 2008. A New Paradigm in Cardiovascular Disease Management.
101. 2007 Cardiovascular Biomarkers and Surrogate Endpoints Symposium, North Bethesda, Maryland, October 17, 2007. Lipoprotein Measurement Current Issues.

LOCAL AND REGIONAL LECTURES

1. Laboratory Group, Yakima, WA, April 27, 1978. Measurement of High Density Lipoproteins.
2. Issaquah Rotary Club, Issaquah, WA, May 10, 1978. Cholesterol and Heart Disease.
3. Seminar - LRC Staff, Seattle, WA, January 9, 1979. HDL Measurement.
4. Dentist's Study Group, Issaquah, WA, January 1979. Lipoproteins and Heart Disease.
5. Northwest Lipid Research Center, Seattle, WA, May 27, 1980. HDL Subfractionation.
6. Madigan Army Medical Center, Tacoma, WA, January, 1981. Annual State of the Fat Message.
7. American Association for Clinical Chemistry Local Workshop on Apolipoprotein Quantitation, Seattle, WA, May, 1981. The Role of Apolipoproteins in Coronary Risk Assessment.

8. LDS Church Issaquah I Ward, Issaquah, WA, Jan 9, 1982. Cardiovascular Disease Prevention.
9. LDS Church Issaquah II Ward, Issaquah, WA, October 12, 1982, Cardiovascular Disease Prevention.
10. University of Washington Bioengineering Colloquium, Seattle, WA, April 1983. High Density Lipoprotein Measurement.
11. Tacoma General Hospital School of Medical Technology, Tacoma, WA, February 22, 1984. Lipid Metabolism and Clinical Correlation of Lipoprotein Data.
12. LDS Church Relief Society, Issaquah, WA, September 27, 1984. Hard Facts about Hard Fats.
13. Northwest Lipid Research Clinic, Seattle, WA, June 1986. Cholesterol Screening Techniques.
14. Shoreline Community College, Seattle, WA, February 17, 1987. Measurement of Lipids and Lipoproteins.
15. Department of Laboratory Medicine Seminar, Seattle, WA, October 7, 1987. High Density Lipoprotein Measurement.
16. Eastside Medical Laboratory, Bellevue, WA, October 18, 1987. High Density Lipoprotein Measurement.
17. University of Washington Endocrinology Days, Seattle, WA, November 6, 1987. Use of the Laboratory in Evaluating Hyperlipoproteinemia.
18. American Association for Clinical Chemistry, Pacific Northwest Section Meeting, Seattle, WA, December 7, 1988. National Cholesterol Education Program: Guidelines for Cholesterol Screening.
19. Washington Department of Social and Health Services Division of Health Cardiovascular Risk Reduction Program, Annual Contractors Meeting, Seattle, WA, December 2, 1988. Reflotron Quality Control Issues.
20. American Association for Clinical Chemistry Pacific Northwest Section, Current Issues in Clinical Laboratory Science Symposium, Bellevue, WA, May 12, 1989. Recommendations for Cholesterol Standardization from the Laboratory Standardization Panel.
21. Pacific Northwest Lipid Club, Seattle, WA, September 16, 1989. Cholesterol Measurement.
22. Public Cholesterol Screening Session, Valley General Medical Center, Renton, WA, February 22, 1990. Quality Control in Cholesterol Screening.
23. American Association for Clinical Chemistry Pacific Northwest Section Meeting, Seattle, WA, September 23, 1992. Update on Lipid and Lipoprotein Analysis.
24. Madigan Army Medical Center, Tacoma, WA, February 10, 1995. Update on Lipid and Lipoprotein Analysis.
25. Washington Society of Clinical Laboratory Scientists, Everett, WA, April 27, 2002, Emerging CVD Risk Factors.
26. American Association for Clinical Chemistry, Northern California Section of AACC, April 19th, 2007. HDL – Not All / Always Good: Current Understanding of HDL in Assessment of CVD Risk.
27. ASCLS-HI/CLMA Aloha Chapter Joint Annual Meeting, Honolulu, HI, May 17, 2007. Moving Beyond HDL-C: Current Understanding of HDL in Assessment of CVD Risk.
28. Lakeside Heart Attack, Stroke, and Diabetes Prevention Symposium, Charlotte, NC, September 29, 2007. Lipoprotein Measurement: Past, Present, Future.

PUBLICATIONS

1. Warnick GR, Burnham BF. Regulation of porphyrin biosynthesis: purification and characterization of delta-aminolevulinic acid synthase. *J Biol Chem* 1971;246:6880-5.
2. Lipid Research Clinics Program. Manual of Laboratory Operations, Vol. 1, DHEW Publication No. (NIH) 75-628, 1974.
3. Albers JJ, Cabana VG, Warnick GR, Hazzard WR. Lp(a) lipoprotein: relationship to sinking pre-beta lipoprotein, hyperlipoproteinemia, and apolipoprotein B. *Metabolism* 1975; 24:1047-1054.

4. Warnick GR, Albers JJ. Physiological and analytical variation in cholesterol and triglycerides. *Lipids* 1976;11/3:203-8.
5. Bachorik PS, Wood PD, Warnick R, et al. Plasma high-density lipoprotein cholesterol concentrations determined after removal of other lipoproteins by heparin manganese precipitation or by ultracentrifugation. *Clin Chem* 1976;22/11:1828-1834.
6. Albers JJ, Warnick GR, Hazzard WR. Type III hyperlipoproteinemia: a comparative study of current diagnostic techniques. *Clin Chemica Acta* 1977;75/2:193-204.
7. Laboratory Methods Committee of the Lipid Research Clinics Program of the National Heart, Lung and Blood Institute. Cholesterol and triglyceride concentrations in serum/plasma pairs. *Clin Chem* 1977;23/1:60-63.
8. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. *J Lipid Res* 1978;19/1:65-76.
9. Albers JJ, Warnick GR, Wiebe D, King P, et al. Multi-laboratory comparison of three heparin-Mn²⁺ precipitation procedures for estimating cholesterol in high-density lipoprotein. *Clin Chem* 1978;24/6:853-6.
10. Warnick GR, Albers JJ. Heparin-Mn²⁺ quantitation of high density lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. *Clin Chem* 1978;24/6:900-4.
11. Albers JJ, Warnick GR, Cheung MC. Quantitation of high density lipoprotein. *Lipids* 1978;13/12:925-32.
12. Warnick GR, Mayfield C, Albers JJ, Hazzard WR. Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type III. *Clin Chem* 1979;25/2:279-284.
13. Warnick GR, Cheung MC, Albers JJ. Comparison of current methods for high-density lipoprotein cholesterol quantitation. *Clin Chem* 1979;25/4:596-604.
14. Mayfield C, Warnick GR, Albers JJ. Evaluation of commercial heparin preparations for use in the heparin-Mn²⁺ method for measuring HDL cholesterol in high-density lipoprotein. *Clin Chem* 1979;25/7:1309-13.
15. Warnick GR, Albers JJ. HDL cholesterol quantitation: comparison of six precipitation methods and ultracentrifugation. HDL Methodology Workshop, Report of the high density lipoprotein methodology workshop, San Francisco, CA 1979 March 12-14, K. Lippel, Ed., USDHEW Publication No. (NIH) 79-1661.
16. Warnick GR, Albers JJ. HDL cholesterol quantitation. *American Association of Bioanalysts: Test of the Month* 1979; 5/4:1-4.
17. Hazzard WR, Warnick GR, Utermann G, Albers JJ, Lewis B. The complex genetics of type III hyperlipoproteinemia: the influence of co-inherited monogenic hyperlipidemia upon the phenotypic expression of apolipoprotein E3 deficiency. In, *Atherosclerosis V. Proceedings of the 5th International Symposium*, Gotto AM, Smith LC, Allen B, Springer-Verlag, Eds. 1980:260.
18. Warnick GR, Albers JJ, Leary ET. HDL cholesterol: results of interlaboratory proficiency tests. *Clin Chem* 1980;26/1:169-70.
19. Albers JJ, Warnick GR, Johnson N, et al. Quality control of plasma high density lipoprotein cholesterol measurement methods: The Lipid Research Clinics Program Prevalence Study. *Circulation* 1980;62 (4 P+2):IV9-18.
20. Albers JJ, Warnick GR, Hazzard WR. Assay methods for high density lipoproteins and their clinical applications. In, *High-Density Lipoproteins*. Day CE, Ed. Marcel Dekker Inc., New York, NY 1981.
21. Warnick GR, Mayfield C, Albers JJ. Evaluation of quality-control materials for high density lipoprotein cholesterol quantitation. *Clin Chem* 1981;27/1:116-23.
22. Albers JJ, Warnick GR. Lipoprotein measurement in the clinical laboratory. *Laboratory Management* 1981;19/2:31-38.
23. Hazzard WR, Warnick GR, Utermann G, Albers JJ. Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: relationship to dysbetalipoproteinemia and hyperlipidemia. *Metabolism* 1981;30/1:79-88.

24. Hazzard WR, Miller N, Albers JJ, Warnick GR, Baron P, Lewis B. The coincidence of isoapolipoprotein E3 deficiency with heterozygous familial hypercholesterolemia: implications for lipoprotein physiology. *Lancet* 1981;1/8215:298-301.
25. Wahl PW, Warnick GR, Albers JJ, Hoover JJ, Walden CE, Bergelin RO, Ogilvie JT, Hazzard WR, Knopp RH. Distribution of lipoprotein triglyceride and lipoprotein cholesterol in an adult population by age, sex, and hormone use: The Pacific Northwest Bell Telephone Co. Health Survey. *Atherosclerosis* 1981;39:111-124.
26. Knopp RH, Warnick GR, Walden CE, Wahl PW, Hoover JJ, Bergelin RO, Ogilvie JT, Albers JJ, Hazzard WR. Relationships of gender, sex hormone use, and age with lipoprotein cholesterol/triglyceride ratios in an adult population: The Pacific Northwest Bell Telephone Co. Health Survey. *Atherosclerosis* 1981;39/2:133-46.
27. Warnick GR, Albers JJ, Bachorik PS, et al. Multi-laboratory evaluation of an ultrafiltration procedure for high density lipoprotein cholesterol quantification in turbid heparin-manganese supernates. *J Lipid Res* 1981;22:1015-1019.
28. Warnick GR, Albers JJ. Technical considerations in quantitation of HDL cholesterol. *Clinica E Laboratorio* 1981;5/2:116-133.
29. Knopp RH, Walden CE, Wahl PW, Warnick GR, et al. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: Relationships to estrogen and progesterone potency. *J Clin Endo Metab* 1981;53/6:1123-1132.
30. Warnick GR, Yu C. Cholesterol, Liebermann-Burchard method with 2-propanol extraction. In, Faulkner WR, *Selected Methods for the Small Clinical Laboratory* 1982;9:175-178.
31. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg²⁺ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. *Clin Chem* 1982;28/6:1379-1388.
32. Warnick GR, Nguyen T, Bergelin RO, Wahl P, Albers JJ. Lipoprotein quantification: an electrophoretic method compared with the Lipid Research Clinics method. *Clin Chem* 1982;28/10:2116-2120.
33. Taggart HM, Applebaum-Bowden D, Haffner S, Warnick GR, Cheung MC, et al. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. *Metabolism* 1982;31/11:1147-52.
34. Warnick GR, Mayfield C, Benderson J, Chen JS, Albers JJ. HDL cholesterol quantitation by phosphotungstate-Mg²⁺ and by dextran sulfate-Mn²⁺ polyethylene glycol precipitation, both with enzymic cholesterol assay compared with the Lipid Research method. *Am J Clin Path* 1982;78/5:718-723.
35. Cooper GR, Ed., In *Selected Methods of Clinical Chemistry*, Washington D.C:AACC Press, 1983;10:91-99.
36. Warnick GR, Benderson JM, Albers JJ. Interlaboratory proficiency survey of high density lipoprotein cholesterol measurement. *Clin Chem* 1983;29/3:516-519.
37. Walden CE, Wahl PW, Knopp RH, Warnick GR, Ogilvie JT, Hazzard WR, Hoover JJ, Albers JJ. Hyperlipidemia in the Pacific Northwest Bell Telephone Company Health Survey: Part 1 lipoprotein cholesterol and triglyceride concentrations. *Arteriosclerosis* 1983;3/2:117-24.
38. Walden CE, Knopp RH, Wahl PW, Hoover JJ, Albers JJ, Hazzard WR, Ogilvie JT, Warnick GR. Hyperlipidemia in the Pacific Northwest Bell Telephone Company Health Survey: Part 2. Lipoprotein lipid interrelationships. *Arteriosclerosis* 1983;3/2:125-31.
39. Warnick GR, Lum C. Evaluation of the Boehringer Mannheim "high performance" test combination for serum cholesterol: comparison to CDC reference and LRC methods. In, Warnick GR, Ed. *Recent Advances in Lipid and Lipoprotein Analysis*. Boehringer-Mannheim Diagnostics. July 1983:17-21.
40. Hazzard WR, Wahl PW, Gagne C, Applebaum-Bowden D, Warnick GR, Albers JJ. Plasma and lipoprotein lipid responses to four hypolipid drugs. *Lipids* 1984;19/2:73-9.
41. Albers JJ, Warnick GR, Nichols AV. Laboratory measurement of HDL. In, Miller GJ, Miller NE, Eds. *Clinical and metabolic aspects of high-density lipoproteins* 1984:381-414.

42. Wahl PW, Walden CE, Knopp RH, Warnick GR, Hoover JJ, Hazzard WR, Albers JJ. Lipid and lipoprotein triglyceride and cholesterol interrelationships: effects of sex, hormone use, and hyperlipidemia. *Metabolism* 1984;33/6:502-8.
43. Benderson J, Warnick GR, Albers JJ. Evaluation of assayed chemistry control pools for measurement of high density lipoprotein. *Clin Chem* 1984;30/1:168-9.
44. Haffner SM, Applebaum-Bowden D, Wahl PW, Hoover JJ, Warnick GR, Albers JJ, Hazzard WR. Epidemiological correlates of high density lipoprotein subfractions, apolipoproteins AI, AII, and D and lecithin cholesterol acyltransferase: the effects of smoking, alcohol, and adiposity. *Arteriosclerosis* 1985;5/2:169-77.
45. Applebaum-Bowden D, Haffner SM, Wahl PW, Hoover JJ, Warnick GR, Albers JJ, Hazzard WR. Post-heparin plasma triglyceride lipase: relationships with very low density lipoprotein triglyceride and high density lipoprotein cholesterol. *Arteriosclerosis* 1985;5/3:273-82.
46. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, Burrows E, Retzlaff B, Poole M. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. *Metabolism* 1985;34/7:642-50.
47. Warnick GR, Nguyen T, Albers JJ. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. *Clin Chem* 1985;31/2:217-22.
48. Warnick GR. Analyzed controls for lipid analysis available. *Clin Chem* 1985;31/4:661.
49. Warnick GR. Apolipoproteins. *CCN* September 1985/8,9.
50. Pan XP, Walden CE, Warnick GR, Hu SX, Albers JJ, Cheung M, Bierman EL. Comparison of plasma lipoproteins and apoproteins in Chinese and American non-insulin dependent diabetic subjects and controls. *Diabetes* 1986;9/4:395-400.
51. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. In: Albers JJ, Segrest JP (Eds.), *Plasma lipoproteins part B; characterization, cell biology, and metabolism. Methods in Enzymology*: 1986;129:101-23.
52. Warnick GR, Lum C, Knopp RH. Kodak Ektachem HDL kit evaluated for HDL cholesterol measurements with the DT-60 instrument. *Clin Chem* 1986;32/10:1988.
53. Knopp RH, Walden CE, Warnick GR, Albers JJ, Ginsberg J, McGinnis BM. Effects of fenofibrate treatment on plasma lipoprotein lipids, HDL cholesterol subfractions, and apolipoproteins B, AI, AIII and E. *Am J Med* 83 1987;83/5B:75-84.
54. Taylor GO, Albers JJ, Warnick GR, Adolphson JL, McFarlane H, Sullivan DR, West CE, Sri-Hari V, Edwards R. Studies of lipoproteins and fatty acids in maternal and cord blood of two racial groups in Trinidad. *Lipids*, 1987;22/3:173-7.
55. Warnick GR, Clapshaw P. Availability of plasma with target values for certain lipids. *Clin Chem News* 1987;33/12:2323-4.
56. Warnick GR. Apolipoproteins. *CCN* June 1988/5. (Letter)
57. McMillan TA, Warnick GR. Interlaboratory proficiency survey of cholesterol and high-density lipoprotein cholesterol measurement. *Clin Chem* 1988;34/8:1629-32.
58. Naito HK, Warnick GR (Consultant). Current status of blood cholesterol measurement in clinical laboratories in the United States: a report from the Laboratory Standardization Panel of the National Cholesterol Education Program. *Clin Chem* 1988;34/1:193-201.
59. Warnick GR. Measurement of cholesterol, triglycerides and HDL: using compact analysis systems. In, Rifkind B, Lippel K, Eds. *Clinics in Laboratory Medicine*. March 1989;9/1:73-88.
60. Warnick GR, Spain M, Kloeppfer H, Volke TM. Standardization of a commercial (Boehringer Mannheim Diagnostics) enzymic method for cholesterol. *Clin Chem* 1989;35/3:409-13.

61. Warnick GR, Kloepper H. National Cholesterol Education Program: Overview, clinical guidelines and cholesterol standardization. Boehringer Mannheim Diagnostics, 1989.
62. Wu LL, Warnick GR, Wu JT, Williams RR, Lalouel JM. A rapid micro-scale procedure for determination of the total lipid profile. Clin Chem 1989;35/7:1486-1491.
63. Bachorik PS, Bradford RH, Cole T, Frantz I, Gotto AM Jr, Roberts K, Warnick GR, Williams OD. Accuracy and precision of analyses for total cholesterol as measured with the reflotron cholesterol method. Clin Chem 1989;35/8:1734-39.
64. Coates RJ, Weiss NS, Daling JR, Rettmer RL, Warnick GR. Cancer risk in relation to serum copper levels. Cancer Research, 1989;49/15:4353-6.
65. Warnick GR. Interview: Biological variability in cholesterol measurement. Medical Management Dynamics, October 1989.
66. Applebaum-Bowden D, McLean P, Steinmetz A, Fontana D, Matthys C, Warnick GR, Albers JJ, Hazzard WR. Lipoprotein, apolipoprotein and lipolytic enzyme changes following estrogen administration in postmenopausal women. J of Lipid Res, 1989;30/12:1895-906.
67. Buist S, Dennis B, Stamler J, Warnick GR, et al. Data from USA-PRC collaborative study of cardiovascular and cardiopulmonary epidemiology. Data Preview, pub. U.S. Department of Health and Human Services, June, 1989.
68. Bachorik P, Cooper G, Warnick GR, et al. Recommendations for improving cholesterol measurement, a report from the Laboratory Standardization Panel of the National Cholesterol Education Program. U.S. Department of Health and Human Services, National Institutes of Health, Publication No. 90-2964, February 1990.
69. McCann BS, Warnick GR, Knopp RH. Changes in plasma lipids and dietary intake accompanying shifts in perceived workload and stress. Psychosomatic Medicine 1990;52/1:97-108.
70. Warnick GR, Knopp RH, Fitzpatrick V., Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald algorithm is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990;36/1:15-19.
71. Warnick GR, Kloepper H, Leary ET, Myers G. The measurement of lipid and lipoprotein risk factors: In pursuit of accuracy. Diagnostics & Clinical Testing 1990;27/5:29-38.
72. Myers G, Warnick GR, Kloepper H, Leary ET. The measurement of lipid and lipoprotein risk factors: in pursuit of accuracy, Part II: Standardization of cholesterol measurements. Diagnostics & Clinical Testing 1990;28:30-33.
73. Warnick GR. National Cholesterol Education Program. CCN, May 1990:2-4.
74. Warnick GR. Laboratory measurement of lipid and lipoprotein risk factors: In pursuit of accuracy. Diagnostics & Clinical Testing May 1990;50/198:9-19.
75. US Lipid Research Clinics Group 1. Blood cholesterol screening in several environments using a portable, dry-chemistry analyzer and fingerstick blood samples. American Journal of Cardiology 1990;65:6-13.
76. Kloepper H, Warnick GR, Leary ET. Cholesterol: Analyte of the decade, Part I: Evidence and challenge. Monitor June 1990;4-23.
77. Kloepper H, Warnick GR, Leary ET. Cholesterol: Analyte of the decade, Part II: The National Cholesterol Education Program. Monitor August 1990;4-30.
78. Kloepper H, Warnick GR, Leary ET. Cholesterol: Analyte of the decade, Part III: Accuracy of laboratory measurements, prerequisite for successful intervention. Monitor December 1990;4-24.
79. Warnick GR. HDL Cholesterol methodological considerations and laboratory performance. International Symposium on Multiple Risk Factors in Cardiovascular Disease, Washington, D.C., December 10-12, 1990.
80. Warnick GR. Separation and quantitation of lipoproteins. Current Opinion in Lipidology, December 1990;1/6:493-499.

81. Kloepfer H, Warnick GR, Leary ET. Cholesterol: Analyte of the decade, Part IV: Drug therapy indications, mechanisms and effects. *Monitor* March 1991;4-22.
82. Rifai N, Warnick GR, eds. *Methods for clinical laboratory measurement of lipid and lipoprotein risk factors*. AACC Press: Washington D.C., 1991.
83. Wiebe DA, Warnick GR. Measurement of high density lipoprotein cholesterol concentration. *Methods for Clinical Laboratory Measurement of Lipid and Lipoprotein Risk Factors*. AACC Press, 1991;61-74.
84. Belcher JD, McNamara JR, Grinstead GF, Rifai N, Warnick GR, Bachorik P, Frantz I Jr.. Measurement of low density lipoprotein cholesterol concentration. *Methods for Clinical Laboratory Measurement of Lipid and Lipoprotein Risk Factors*. AACC Press, 1991;75-86.
85. Warnick GR. Fingerstick specimens can be equivalent to venous for cholesterol measurement. *The Fats of Life, AACC Lipids and Lipoproteins Division Newsletter*, Summer 1991;V/3:6-7.
86. Warnick GR. Compact analysis systems for cholesterol, triglycerides and high-density lipoprotein cholesterol. *Current Opinion in Lipidology, Current Science* 1991;2:343-348.
87. Warnick GR. Recent developments in alternate site testing. *The Fats of Life, AACC Lipids and Lipoproteins Division Newsletter*, Winter 1991;V/4:1,13.
88. Tao S, Runchao C, Warnick GR, *et al.* Serum lipids and their correlates in Chinese urban and rural populations of Beijing and Guangzhou. *International Journal of Epidemiology*.
89. Peoples Republic of China - United States Cardiovascular and Cardiopulmonary Epidemiology Research Group. An epidemiologic study of cardiovascular and chronic obstructive pulmonary disease risk factors in four populations in the People's Republic of China: the US-PRC collaborative study of cardiovascular epidemiology. (Members: Buists, Dennis B, Hurd, Stamler J, Taylor J, Warnick R, Williams D.) *Circulation* 1992, 85:3;1083-1096.
90. Warnick GR, Boerma GJM, Assmann G, *et al.* Multi-center evaluation of Reflotron HDL cholesterol: A direct dry-chemistry assay suitable for fingerstick specimens. *Clin Chem* 1992.
91. Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz ID Jr. Measurement of low-density lipoprotein cholesterol in serum: a status report. *Clin Chem* 1992;38/1:150-60.
92. Warnick GR, Boerma GJ, Assmann G, Endler AT, Gerique G, Gotto AM, Graziani MS, Lippi U, Patsch W, Riesen WF, *et al.* Multicenter evaluation of Reflotron direct dry-chemistry assay of high-density lipoprotein cholesterol in venous and fingerstick specimens. *Clin Chem* 1993;39/2:271-7.
93. McNamara JR, Huang C, Massov T, Leary ET, Warnick GR, Rubins HB, Robins SJ, Schaefer EJ. Modification of the dextran-Mg²⁺ high-density lipoprotein cholesterol precipitation method for use in previously frozen plasma. *Clin Chem* 1994;40/2:233-9.
94. Belcher JD, McNamara JR, Grinstead GF, Rifai N, Warnick GR, Bachorik P. Measurement of low density lipoprotein cholesterol concentration. In: Rifai N, Warnick GR, eds. *Laboratory Measurement of Lipids, Lipoproteins, and Apolipoproteins*. Washington DC:AACC Press, 1994:107-123.
95. Wiebe DA, Warnick GR. Measurement of high-density lipoprotein cholesterol concentration. In: Rifai N, Warnick GR, eds. *Laboratory Measurement of Lipids, Lipoproteins, and Apolipoproteins*. Washington DC:AACC Press, 1994, 91-105.
96. Belcher JD, McNamara JR, Grinstead GF, Rifai N, Warnick GR, Bachorik P. Measurement of low-density lipoprotein cholesterol concentration. In: Rifai N, Warnick GR, eds. *Laboratory Measurement of Lipids, Lipoproteins, and Apolipoproteins*. Washington DC:AACC Press, 1994, 107-123.
97. Warnick GR. Measurement and clinical significance of high-density lipoprotein cholesterol subclasses. In: Rifai N, Warnick GR, eds. *Laboratory Measurement of Lipids, Lipoproteins, and Apolipoproteins*. Washington DC:AACC Press, 1994, 207-22.
98. Warnick GR. Lipoprotein (a) is included in low-density lipoprotein by NCEP definition. *Clin Chem*, 1994;40/11:2115-6.

99. Warnick GR, Leary ET, Ammirati EB, Allen MP. Cholesterol in fingerstick capillary specimens can be equivalent to conventional venous measurements. *Arch Pathol Lab Med*, 1994;118:1110-4.
100. Warnick GR. Capabilities of compact analyzers for decentralized testing of lipids and lipoproteins. *Atherosclerosis (Suppl.)*, 1994;108:S171-9.
101. Bachorix PS, Ross JW. for the National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: Executive Summary. *Clinical Chemistry*, 1995;41:1414-1420.
102. Warnick GR, and National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for triglyceride measurement. Executive Summary. *Clinical Chemistry*, 1995;41:1414-1420.
103. Warnick GR, primary author; with National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for measurement of high density lipoprotein cholesterol. Executive Summary. *Clinical Chemistry*, 1995;41:1414-1420.
104. Warnick GR, Measuring cholesterol and other lipoproteins and vascular diseases in cardiovascular risk assessment. In: Rifkind (ed), *Lowering Cholesterol in High Risk Individuals and Populations*, Marcel Dekker, Inc., 1995.
105. Warnick GR, Leary ET. Analytical procedures for measurement of the lipids and lipoproteins. In: Spiller (ed), *The CRC Handbook of Lipids in Human Nutrition*, CRC Press, 1995.
106. Pisani T, Gebiski CP, Leary ET, Warnick GR, Ollington JF. Accurate, direct determination of low density lipoprotein cholesterol using an immunoseparation reagent and enzymatic cholesterol assay. In: McLendon (ed), *Archives of Pathology and Laboratory Medicine*, December, 1995;119:1127-1135.
107. McNamara JR, Warnick GR, Leary ET, Wittells E, Nelson FE, Pearl MF, Schaefer EJ. Multi-center evaluation of a patient-administered test for blood cholesterol measurement. *Preventive Medicine*, 1996, Vol 25, 583-92.
108. Warnick GR, McNamara JR, Wu LL. Lipids and lipoproteins. In: Bishop ML, Dubin-Engelkirk JL, Fody EP (ed), *Clinical Chemistry, Principles, Procedures, Correlations*, Third Edition, pp. 313-340, Philadelphia, PA: JB Lippincott Co, 1996.
109. Rifai N, Warnick DR, Dominiczak M, eds. *Handbook of Lipoprotein Testing*. AACC Press: Washington D.C., 1997.
110. Wiebe D, Warnick GR. Measurement of high-density lipoprotein cholesterol. In: Rifai N, Warnick GR, Dominiczak MH. eds. *Handbook of Lipoprotein Testing*. Washington DC: AACC Press, 1997.
111. Warnick, GR, Measurement and clinical significance of high-density lipoprotein cholesterol subclasses. *Handbook of Lipoprotein Testing*. AACC Press, Washington D.C., 1997.
112. Hart MK, Hart RF, Warnick GR, Glasgow RE. Evaluations of a clinical measurement process and the QC procedures monitoring It. *Quality Engineering*, 1997;9:4.
113. Leary ETL, Warnick, GR, Baker D, et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particles-cholesterol in serum and plasma. *Clin Chem*, 1998;44:12:2490-98.
114. Warnick, GR, Measurement of HDL-cholesterol by homogeneous assays. *Diagnostic Endocrinology, Immunology and Metabolism*. American Association for Clinical Chemistry, 1999.
115. Sarno M, Powell H, Tjersland G, Schoendorfer D, Harris H, Adams K, Ogata P, Warnick GR. A collection method and high-sensitivity enzyme immunoassay for sweat pyridinoline and deoxypyridinoline cross-links. *Clin Chem* 1999;45:1501-9.
116. Wang T, Nakajima K, Leary ET, Warnick GR, Cohn JS, Hopkins PN, Wu LL, Cilla DD, Zhong J, Havel RJ. Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial type III hyperlipoproteinemia. *Clin Chem* 1999;45(11):1981-7.

117. McNamara JR, Warnick GR, Wu LL. Lipids and lipoproteins. In: Bishop ML, Dubin-Engelkirk JL, Fody EP (eds), *Clinical Chemistry, Principles, Procedures, Correlations*, Fourth Edition, pp. 233-460, Philadelphia, PA: JB Lippincott Co, 2000.
118. Rifai N, Warnick GR, Dominiczak MH. eds. *Handbook of Lipoprotein Testing*. Second Edition. Washington DC: AACC Press, 2000:819pp.
119. Nauck M, Wiebe D, Warnick GR. Measurement of high-density lipoprotein cholesterol. In: Rifai N, Warnick GR, Dominiczak MH. eds. *Handbook of Lipoprotein Testing*. Second Edition. Washington DC: AACC Press, 2000:221-44.
120. Warnick GR, Cheung MC. Measurement and clinical significance of high-density lipoprotein subclasses. In: Rifai N, Warnick GR, Dominiczak MH. eds. *Handbook of Lipoprotein Testing*. Second Edition. Washington DC: AACC Press, 2000:311-28.
121. Cole TG, Warnick GR, Rifai N. Providing laboratory support for clinical trials, epidemiological studies, and *In Vivo* diagnostic evaluations. In: Rifai N, Warnick GR, Dominiczak MH. eds. *Handbook of Lipoprotein Testing*. Second Edition. Washington DC: AACC Press, 2000:749-766.
122. Warnick GR. Measurement of cholesterol and other lipoprotein constituents in the clinical laboratory. *Clin Chem Lab Med*, 2000;38:287-300.
123. Kroll MH, Cole TG, Rifai N, Cooper G, Warnick GR, Jialal I. Standardization of lipoprotein reporting. *Am J Clin Pathol*, 2000;114:696-702.
124. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. *Clin Chem* 2001;47:1579-96.
125. Warnick GR, Remaley AT. Measurement of cholesterol in plasma and other body fluids. *Current Atherosclerosis Reports* 2001;3:404-11.
126. Warnick GR. Biochemical and clinical perspectives. Geneva, Switzerland. March 24-25, 2000. Variation in biochemical markers of bone turnover: sources, quantification, minimization. Published: Eastell R, Baumann M, Hoyle NR, Wiczorek L. eds. *Bone Markers, Biochemical and Clinical Perspectives*, London, Martin Dunitz Ltd. 2001:131-9.
127. Sarno M, Sarno L, Baylink D, Drinkwater B, Farley S, Kleerekoper M, Lang R, Lappe J, Licata A, McClung M, Miller P, Nattrass S, Recker R, Schwartz EN, Tucci JR, Wolf S, Powell H, Tjersland G, Warnick GR. Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease. *Clin Chem Lab Med* 2001;39(3):223-8.
128. Nauck M, Warnick GR, Rifai N. Methods for measurement of low-density lipoprotein cholesterol: a critical assessment of direct measurement by homogeneous assay versus calculation. *Clin Chem* 2002;48:236 - 254.
129. Vesper WV, Demers LM, Eastell R, Garner P, Kleerekoper M, Robins SP, Srivastava AK, Warnick GR, Watts NB, Myers G. Assessment of factors contributing to biological variability of urinary pyridinoline and deoxypyridinoline measurement: Guidelines on preanalytical criteria. *Clin Chem* 2002;48:220-235.
130. Warnick GR, Myers G, Cooper G, Rifai N. Impact of the third cholesterol report from the Adult Treatment Panel of the National Cholesterol Education Program on the clinical laboratory. *Clin Chem*, 2002;48:11-17.
131. Warnick GR, Miller WG, Waymack PM, Anderson FP. Lack of agreement of homogeneous assays with the reference method for LDL-cholesterol may not indicate unreliable prediction of risk for cardiovascular disease. *Clin Chem*, 2002;48:1812-5.
132. Expert Panel. AHA/CDC Scientific statement: markers of inflammation and cardiovascular disease. *Circulation* 2003;107:499-511.
133. Rifai N, Cooper GR, Brown VR, Friedewald W, Havel RJ, Myers GL, Warnick GR. *Clinical Chemistry Journal* has contributed to progress in lipid and lipoprotein testing for fifty years. *Clin Chem*, 2004;50:1861-70

134. Remaley AT, McNamara JR, Warnick GR. Lipids and lipoproteins. In: Bishop ML, Fody EP, Schoeff L (eds), *Clinical Chemistry, Principles, Procedures, Correlations*, Fifth Edition, pp. 282-313, Philadelphia, PA. Lippincott Williams & Wilkins, 2005.
135. Rifai N, Warnick GR. Lipids, Lipoproteins and apolipoproteins. In: *Tietz Textbook of Clinical Chemistry*, Third Edition. Burtis CA, Ashwood ER (eds). Philadelphia PA. W B Saunders 2005.
136. Spitzer S, Warnick GR. The role of expanded cholesterol and lipoprotein subclass testing in assessing cardiovascular disease (CVD) risk. *Life Sciences BTR*. 2005;5:48-51.
137. McNamara JR, Warnick GR, Cooper GR. A brief history of lipid and lipoprotein measurements and their contribution to clinical chemistry. *Clin Chim Acta* 2006 Jul 23;369(2):158-67.
138. Remaley AT, Rifai N., Warnick GR. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. In: *Tietz handbook of Clinical Chemistry*, Third Edition. Burtis Ca, Ashwood ER, Bruns DE (eds). Philadelphia PA W B Saunders; 2006.
139. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, McConnell JP. Lipoprotein-associated phospholipase A₂: review and consensus panel recommendation of a clinical cutpoint for adults. *Prev Cardiol*; 2006 Summer;9(3):138-43.
140. Warnick Gr, McNamara JR, Boggess CN, Clendenen F, Williams PT, Landolt CC. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. *Clinics in Laboratory Medicine*; Donald Smith (guest editor); Vol 26; No 4:803-46; Dec 2006.
141. Warnick GR, Remaley AT, Boggess C, Mallory T, Chao-Shern C. Lipoprotein subclasses in cardiovascular disease risk assessment and patient management. *Clin Lab Int'l*. 2007; Sept.
142. Remaley AT, Warnick GR. Part I & II : Beyond HDL-C: the changing paradigm for HDL testing. *Clin Lab News*. 2007, Nov & Dec.
143. Remaley AT, Rifai N., Warnick GR. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. In: *Tietz textbook of Clinical Chemistry*, John Wiley & Sons, Inc. 2007. 6th ed.
144. Warnick GR, Nakajima K. Fasting versus nonfasting triglycerides: implications for laboratory measurements. *Clin Chem*, November 26th. 2007.
145. Warnick GR. High-density lipoproteins: the neglected stepchildren whose importance as a risk factor continues to be defined. *Clin Chem* 54:5 923-924 February 15, 2008.
146. Warnick GR, Baca A. Estimation of LDL-associated apolipoprotein B from measurements of triglycerides and total apolipoprotein B. *Clin Chem*. 2008 May;54(5):782-4.
147. Remaley AT, Warnick GR. High-density lipoprotein: what is the best way to measure its antiatherogenic potential? *Expert Opinion on Medical Diagnostics*, Jul 2008, Vol. 2, No. 7, Pages 773-788.
148. Warnick GR. Standardization of measurements for cholesterol, triglycerides, and major lipoproteins. *Lab Med*. 2008 August; vol 39 (8):481-490.

ABSTRACTS

1. Thompson RH, Warnick GR, Brunham BF. Purification and characterization of delta-aminolevulinic acid synthase from rhodopseudomonas spheroids: hemin inhibition. *American Society of Biological Chemists. Fed Proc* 1971.
2. Warnick GR, Albers JJ. Modification of the heparin-Mn²⁺ precipitation technique for more accurate quantitation of high density lipoprotein cholesterol in plasma. *Clin Chem* 1977;23/6:1152.
3. Warnick GR, Albers JJ, Hazzard WR. Genetics of type III hyperlipoproteinemia; "pseudodominant" transmission in a large kindred. *Circulation* 1977;part II suppl 56:III-21.
4. Albers JJ, Warnick GR, Cheung MC. High density lipoprotein (HDL) quantitation. *J Am Oil Chem Soc* 1978;55:234A.

5. Warnick GR, Albers JJ. A comparison of current methods for high density lipoprotein cholesterol quantitation. Clin Chem 1978;23/6:1025.
6. Warnick GR, Albers JJ. High-density-lipoprotein cholesterol (HDL CH) quantitation: effect of plasma storage on heparin-Mn²⁺ supernatant cholesterol concentration. Clin Chem 1979;25/6:1098.
7. Warnick GR, Albers JJ. Evaluation of quality control (QC) materials for high-density-lipoprotein cholesterol (HDL-CH) separation. Clin Chem 1980;26/7:998.
8. Knopp RH, Mabuchi H, Warnick GR, Price T, Cheung M, Chen C-H, Albers J. Xanthomatosis and lipoprotein X (LpX): effects of plasmapheresis. Abstracts of the 53rd Scientific Session of the American Heart Association 1981 November 17-20.
9. Warnick GR, Benderson J, Albers JJ. High density lipoprotein cholesterol (HDL CH) quantification: an optimized dextran-sulfate-Mg²⁺ procedure compared to the Lipid Research Clinic (LRC) heparin-Mn²⁺ method. Clin Chem 1981;27/6:1041.
10. Warnick GR, Nguyen T, Albers JJ. Lipoprotein quantitation by lipidophor electrophoresis (LE) compared to the Lipid Research Clinics (LRC) method. In, Proceeding of the XI International Congress of Clinical Chemistry, IV European Congress of Clinical Chemistry, Vienna, Austria, 1981 August 30 - September 5. J Clin Chem Biochem 1981;19/8:869.
11. Warnick GR, Benderson JM, Albers JJ. Quantitation of high-density- lipoprotein subclasses after separation by dextran sulfate and Mg²⁺ precipitation. Clin Chem 1982;28/7:1574.
12. Walden CE, Wahl PW, Knopp RH, Hoover JJ, Warnick GR, Albers JJ, Hazzard WR. Features of lipoprotein lipids in hypercholesterolemic (HC), hypertriglyceridemic (HTG) and combined hyperlipidemic (CHL) subjects from a defined population. 22nd Conference on Cardiovascular Disease Epidemiology, Dallas, Texas, 1982 March 5-7.
13. Applebaum-Bowden D, Hazzard WR, McLean P, Steinmetz A, Mathis C, Fontana D, Warnick GR, Albers JJ. Estrogen reduces LDL cholesterol on a high cholesterol diet in postmenopausal women. Arteriosclerosis September/October 1982;2:415a.
14. Knopp RH, Ogilvie JT, Warnick GR, Albers JJ. Effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects. Eighth International Symposium on Drugs Affecting Lipid Metabolism, Philadelphia, Pennsylvania, 1983 July 27-30.
15. Warnick GR, Lum C. Cholesterol quantification by an accurate and precise enzymic method. Clin Chem 1983;29/6:1226.
16. Warnick GR, Lum C. An evaluation of the Boehringer Mannheim "high performance" (BMD-HP) cholesterol reagent. Proceedings of the XII International Congress of Clinical Chemistry, Rio de Janeiro, 1984.
17. Pan X, Warnick R, Hu S, Albers J, Cheung M, Walden C, Bierman E. A comparison of plasma lipoproteins in Chinese and American non-insulin dependent diabetics (NIDD). Diabetes 1984;33 suppl 1:624.
18. Novros J, Greenberg N, Powers D, O'Grady M, Shanklin N, Warnick GR. Analysis of HDL-cholesterol in Heparin-Mn²⁺ supernatants using Kodak Ektachem clinical chemistry slides for cholesterol. Clin Chem 1984;30/6:991.
19. Warnick GR. Lipids/lipoprotein measurements in nutritional assessment. Clin Chem 1984;30/6:1088.
20. Applebaum-Bowden BD, Hazzard WR, Haffner S, McLean P, Steinmetz A, Mathis C, Fontana D, Warnick GR, Albers JJ. Rapid changes in hepatic triglyceride lipase in response to sex steroids. VII International Symposium on Atherosclerosis, Melbourne, October 1985.
21. Warnick GR, Lum C. Evaluation of enzymic triglyceride methods modified for glycerol blanking. Clin Chem 1985;31/6:948.
22. Shainholtz S, Drinkwater B, FACSM, Nilson K, Warnick R. Lipid profiles of amenorrheic and eumenorrheic athletes. American College of Sports Medicine Annual Meeting, 1985.

23. Greenberg N, Warnick GR. Differences between EDTA-plasma and serum high-density lipoprotein cholesterol following precipitation with dextran sulfate. *Clin Chem* 1985;31/6:948.
24. Warnick GR, Lum C, Knopp RH. Evaluation of the Kodak Ektachem HDL kit with cholesterol analysis on the DT-60 instrument. *Clin Chem* 1986; 32/6:1098.
25. Warnick GR. Current lipid, lipoprotein and apolipoprotein methods for assessing risk for CHD. *Clin Chem* 1986;32/6:1221.
26. Tao SC, Huang ZD, Tsai RS, Wu XG, Zhou BF, Yu JS, Li YH, Rao XX, Zhang K, Cen RC, Dennis B, Friedewald W, Stammler J, Taylor J, Warnick GR, Williams D. Dietary patterns, serum lipids, urinary electrolytes, and blood pressure: middle-aged male and female workers and farmers in north and south China. X World Congress of Cardiology. Washington, D.C., September 1986.
27. Warnick GR, Lum C, Walden C, Knopp RH. Evaluation of portable analyzers for on-site cholesterol screening. 59th American Heart Association Meeting, Dallas, TX, November 1986.
28. Warnick GR, Lum C, Walden C, Knopp RH. Evaluation of portable analyzers for lipid analysis with emphasis on cholesterol screening. Proceedings IX international symposium on drugs affecting lipid metabolism, Florence, October 1986.
29. Warnick GR. Report on the recommendations of the laboratory standardization panel of the national cholesterol education program. Proceedings of the Society of Armed Forces Medical Laboratory Scientists. Baltimore, 1987;16/1:23-24.
30. Warnick GR. Evaluation of portable analyzers for cholesterol determination. International symposium on cholesterol control and cardiovascular diseases: Prevention and therapy. Milan, 1987.
31. Warnick GR, Cooper GR. National cholesterol education program: current guidelines for diagnosis and treatment of hypercholesterolemia. *Clin Chem* 1988;34/6:1341.
32. Warnick GR. Approach to achieving accurate measurement of cholesterol. *Clin Chem* 1988;34/6:1342.
33. Warnick GR. National cholesterol education program (NCEP) guidelines; Measurement/interpretation of cholesterol and the lipoproteins. Proceedings of the Society of Armed Forces Medical Laboratory Scientists. Baltimore, MD, 1988.
34. Warnick GR. Cholesterol standardization: Method characteristics and specimen matrix interactions. Clinical Laboratory Measurements: Accuracy and Patient Needs. National Institute of Standards and Technology. October 1988.
35. Warnick GR, Branson L. Clinical Laboratory Computer Symposium, 1988.
36. McCann BS, Veith RC, Schwartz RS, Lewis N, Albers JJ, Warnick GR, Knopp RH. Cardiovascular neuro-endocrine, and lipoprotein changes during stress in hyperlipidemic and normolipidemic men. *Psychophysiol* 1988;25:421.
37. Warnick GR. National Cholesterol Education Program: current guidelines for diagnosis and treatment of hypercholesterolemia. *Clin Chem* 1988;34/6:1341.
38. Warnick GR. Approach to achieving accurate measurement of cholesterol. AACC Selected Topics, June 1988;34/6:1342.
39. Nguyen T and Warnick GR, Improved methods for separation of total HDL and subclasses. AACC National Meeting, *Clin Chem* 1989;35/6:1086.
40. Warnick GR. Apolipoprotein E isoform analysis in characterizing atherogenic risk. AACC Selected Topics Session. *Clin Chem* 1989;35/6:1235.
41. Warnick GR. National Cholesterol Education Program (NCEP) guidelines; measurement/interpretation of cholesterol and the lipoproteins. *Journal of Military Medical Laboratory Science* 1989;19/1:68.
42. Zhendong H, Warnick GR, Zhou Y, Stamler J, Li Y, Williams D, Liao Y, Dennis B, Guangzhou Cardiovascular Institute, Guangzhou, PRC. Lipid trends in south China. 2nd International Conference on

Preventive Cardiology and the 29th Annual Meeting of the AHA Council on Epidemiology, Washington, D.C., June 18-22, 1989.

43. Tao S-C, Williams OD, Huang Z, Warnick GR, Zhikui X, Zhou Y, Zhou B, Dennis B, Stamler J, Li Yihe, Li Ying, Fu Wai Hospital, Beijing, PRC. Serum lipids and their correlates in Chinese populations. 2nd International Conference on Preventive Cardiology and the 29th Annual Meeting of the AHA Council on Epidemiology. Washington, D.C., June 18-22, 1989.
44. Warnick GR. Recommendations for achieving acceptable accuracy in measurement of cholesterol and other coronary heart disease risk factors. Journal of Military Medical Laboratory Science, 1990.
45. Warnick GR. A fresh specimen proficiency survey improves laboratory accuracy in lipid analysis. Clin Chem 1990;36/6:963.
46. Warnick GR. HDL Cholesterol: Methodological considerations and laboratory performance. International Symposium on Multiple Risk Factors in Cardiovascular Disease, Washington, D.C., December 10, 1990.
47. Xiao Z, Zhuo Y, Warnick GR, *et al.* Serum uric acid, its correlates, and its relation to blood pressure: findings on urban and rural populations in north and south china. 31st Annual Conference on Cardiovascular Disease Epidemiology, American Heart Association, Orlando, FL, March 14-16, 1991.
48. Belcher J, Cole T, Warnick GR, *et al.* Standardization of cholesterol measurement in clinical and physician office laboratories by the National Cholesterol Reference Methodology Laboratory Network. National Conference on Cholesterol and High Blood Pressure Control, Washington, D.C., April 8-10, 1991.
49. Ammirati E, Allen M, Miller J, Warnick GR, Leary ET, Weaver C. Clinical evaluation of fingerstick sampling vs. venous blood sampling in total cholesterol measurements. Clin Chem 1992;38/6:1059.
50. Baldwin JR, Warnick GR, Leary ET, Baillie E, Hicks D. Rapid, precise automated HDL cholesterol analysis with the Helena REP system. Clin Chem 1992;38/6:1059.
51. Warnick GR. Innovative electrophoretic techniques for lipoprotein analysis. Clin Chem 1992;38/6:1134.
52. Leary ET, Tjersland G, Warnick GR. Evaluation of the genzyme direct quantitation of LDL cholesterol. AACC, December, 1992.
53. Warnick GR, Leary ET, Goetsch J, Hicks D. Electrophoretic quantitation of LDL-cholesterol using the Helena REP. AACC National Convention, July, 1993, New York, NY.
54. McNamara J, Huang C, Massov, T, Leary, ET, Warnick GR, Rubbins, HB, Robins SJ, Schaefer EJ. Modification of the Dextran-MG²⁺ HDL cholesterol precipitation method for use with frozen plasma. AACC, July 1993
55. Warnick GR. Capabilities of compact analyzers for decentralized testing. Atherosclerosis 1993;108(suppl):S171-S179.
56. Leary ET, Tjersland G, Warnick GR, Cornell F. Improved apolipoprotein E phenotyping by polyacrylamide gel isoelectric focusing. Atherosclerosis 1993;108(suppl):S192
57. Warnick GR, Leary ET, Goetsch J. Electrophoretic Quantification of LDL-cholesterol using the Helena REP. Clin. Chem. 1993; 39(6):1122.
58. Leary ET, Tjersland G, Warnick GR, Cornell F, Reed RG. Improved rapid apolipoprotein E phenotyping by isoelectric focusing. Clin Chem, 1994; 40:1102-1103.
59. Kimberly, MM, Waymack PP, Myers GL, Colge TG, Ferguson C Gibson D, Leary ET, Warnick GR. Comparison of precipitation methods for determination of HDL cholesterol in the cholesterol reference method laboratory network, Clinical Chemistry 1994; 40:1105.
60. Warnick GR, Weaver CC, Ward KK, Roberts K. Performance of the Accutrend[®] GC reflectance meter in the analysis of fingerstick glucose and cholesterol. Clin Chem 1995; 41/6:S138.
61. Fu PC, Aota D, Warnick GR, Leary ET, Feistel C. Performance characteristics of a new HDL precipitating reagent (PBI Plus[™]). Clin Chem 1995; 41/6:S141.

62. Tjersland G, Warnick GR, Cole TG. SPINPRO[®]-HDL Qualifies for certification from the CDC cholesterol reference method laboratory network. Clin Chem 1996; 42/6:S289.
63. Leary ET, Wang T, Weiss C, Warnick GR. Comparison between fresh human serum and lyophilized serum for lipid proficiency testing. Clin Chem 1996; 42/6:S292.
64. Warnick GR, Harris H, Doneen, B. Identification of bone-loss markers, Pyridinoline (PYD and Deoxypyridinoline (dPYD), in sweat by HPLC. Clin Chem 1997; 43:S177.
65. Warnick GR, Doneen B., Tjersland G, et al. Bone resorption markers quantified by sensitive immunoassays in non-occlusive multi-day Osteopatch[™] sweat. J Bone Mineral Research 1997; vol 12, supp1: (S585).
66. Powell HK, Adams K, Warnick GR, et al. Development of a more sensitive immunoassay for the routine measurement of pyridinoline in sweat patch extracts. AACC Convention, August 1998, Chicago, IL.
67. Tjersland G, Warnick GR, Powell, H, et al. Female hormones in sweat. Clin Chem, 1998; Chicago, IL.
68. Nuti R, Cauderella R, Warnick GR, et al. Clinical utility of osteopatch sweat pyridinoline. J Bone Mineral Research 1998;23:S627.
69. Sarno L, Baylink D, Warnick GR, et al. Osteopatch sweat pyridinoline is elevated in women with established osteoporosis. J Bone Mineral Research, 1998;23:S514.
70. Powell H, Miller N, Warnick GR. The development of an Elisa for deoxypyridinoline in sweat pad extracts. J Bone Mineral Research 1998;23:S516.
71. Warnick, GR. Lipoproteins: Past, Present and Future. Japanese Journal Clin Pathology, Vol.53;no.9(2005).
72. Sethi AA, Sampson M, Warnick R, Muniz N, Nordestgaard BG, Tybjaerg-Hansen A, Remaley AT. Composition analysis of lipoproteins in patients with ischemic heart disease. Clin Chem, 2007; Vol 53, No. 6 6 (suppl): A45.
73. Sethi AA, Sampson M, Muniz N, Warnick GR, Nordestgaard BG, Tybjcerg-Hansen A, Remaley AT. Composition analysis of high density lipoproteins in patients with extreme HDL-C levels with or without ischemic heart disease. AHA 2007.
74. Sethi AA, Sampson M, Warnick GR, Nordestgaard BG, Tybjcerg-Hansen A, Remaley AT. Pre-beta HDL and lecithin:cholesterol acyltransferase levels are strong positive diagnostic risk markers for ischemic heart disease in subjects with both high and low HDL-C levels in the Copenhagen City Heart Study. Circulation, 2008;118:S370